VIWA-1
Study Design: International phase II trial, explorative, multicenter, open label, and randomized
Patients: treatment naive WM patients
Treatment: Venetoclax, Rituximab
Status of the Study: patient recruitment started
Sponsor: University Hospital of Ulm, PI Christian Buske